LCAS Exam 2026 | Licensed Clinical Addiction Specialist Study Guide & Practice Questions
Medication Assisted Treatment (MAT) - (answer)any treatment for for a SUD that includes a
pharmacologic intervention as part of a comprehensive substance abuse treatment plan with ultimate
goal of patient recovery with full social function
alcohol dependence - (answer)FDA approved disulfiram, naltrexone, and acamprosate for treatment of
____________
opioid dependence - (answer)FDA approved methadone, naltrexone, and buprenorphine for treatment
of _____________
alcohol, nicotine and opioid - (answer)currently, FDA has approved medications effective for MAT in
three types of SUD: _____________, _____________ and __________ dependence
acamprosate, disulfiram, naltrexone - (answer)three drugs approved for alcohol dependence
Acamprosate (Campral) - (answer)used to treat alcohol dependence; reduces symptoms of protracted
withdrawal (i.e. insomnia, anxiety, restlessness, and dysphoria) by normalizing brain systems disrupted
by chronic alcohol consumption; more effective in pts with severe alcohol use disorders
Disulfiram (Antabuse) - (answer)used to treat alcohol dependence; inhibits an enzyme involved in the
metabolism in alcohol, causing unpleasant reaction (i.e. flushing, nausea, and heart palpitations) if
alcohol is consumed after taking the medication; compliance can be a problem but is very effective with
motivated pts.
Naltrexone (Vivitrol or Revia) - (answer)used to treat alcohol dependence; blocks receptors involved in
rewarding effects of drinking and in cravings for alcohol. Reduces relapse of heavy drinking behavior and
is highly effective in some but not all pts., where varied outcomes could be due to genetic factors.
Available in both oral tablet and long-acting injectable form
Methadone, Buprenorphine, Naltrexone - (answer)three FDA approved drugs used in MAT for opioid use
disorders
, LCAS Exam 2026 | Licensed Clinical Addiction Specialist Study Guide & Practice Questions
Methadone - (answer)prevents opioid withdrawal and craving symptoms by activating opiate receptors
in the brain. Long history of use in treatment of opioid dependence.
Buprenorphine - (answer)reduces or eliminates opioid withdrawal symptoms and reduces cravings,
without producing euphoria or dangerous side effects of heroin or other opioids. Activates and blocks
opioid receptors in the brain. Available for sublingual administration in both a stand-alone formula and
in combination with naloxone.
Naltrexone (Vivitrol or Revia) - (answer)approved for prevention of relapse in adult pts. following
complete detox from opioids. Acts by blocking brain's opioid receptors, preventing opioid drugs from
acting on them and thus blocking euphoria the user would normally feel and/or causing withdrawal if
recent opioid use has occurred. Can be taken orally or given in monthly injections
Naloxone (Narcan) - (answer)medication used to prevent opioid overdose deaths. Medication binds to
opioid receptors and can rapidly reverse or block the effects of other opioids.
Individual therapy - (answer)form of behavioral therapy that can help people learn new skills to
maintain a substance-free life, address co-occurring mental health issues, address benefits of using
prescription medication in treatment, and support individuals to pursue meaningful work, school, and
family goals
Group counseling - (answer)form of behavioral therapy that can help reduce a person's sense of
isolation, provide peer support and feedback, and develop social and problem-solving skills
Family behavior therapy - (answer)form of behavioral therapy that provides education, allows family
members to express their feelings and concerns, and helps secure the family's support for the person in
recovery
Cognitive-behavioral therapy - (answer)form of behavioral therapy; seeks to help patients recognize,
avoid, and cope with situations in which they are most likely to abuse drugs
Motivational enhancement - (answer)form of behavioral therapy; capitalizes on readiness of individuals
to change their behavior and enter treatment
Medication Assisted Treatment (MAT) - (answer)any treatment for for a SUD that includes a
pharmacologic intervention as part of a comprehensive substance abuse treatment plan with ultimate
goal of patient recovery with full social function
alcohol dependence - (answer)FDA approved disulfiram, naltrexone, and acamprosate for treatment of
____________
opioid dependence - (answer)FDA approved methadone, naltrexone, and buprenorphine for treatment
of _____________
alcohol, nicotine and opioid - (answer)currently, FDA has approved medications effective for MAT in
three types of SUD: _____________, _____________ and __________ dependence
acamprosate, disulfiram, naltrexone - (answer)three drugs approved for alcohol dependence
Acamprosate (Campral) - (answer)used to treat alcohol dependence; reduces symptoms of protracted
withdrawal (i.e. insomnia, anxiety, restlessness, and dysphoria) by normalizing brain systems disrupted
by chronic alcohol consumption; more effective in pts with severe alcohol use disorders
Disulfiram (Antabuse) - (answer)used to treat alcohol dependence; inhibits an enzyme involved in the
metabolism in alcohol, causing unpleasant reaction (i.e. flushing, nausea, and heart palpitations) if
alcohol is consumed after taking the medication; compliance can be a problem but is very effective with
motivated pts.
Naltrexone (Vivitrol or Revia) - (answer)used to treat alcohol dependence; blocks receptors involved in
rewarding effects of drinking and in cravings for alcohol. Reduces relapse of heavy drinking behavior and
is highly effective in some but not all pts., where varied outcomes could be due to genetic factors.
Available in both oral tablet and long-acting injectable form
Methadone, Buprenorphine, Naltrexone - (answer)three FDA approved drugs used in MAT for opioid use
disorders
, LCAS Exam 2026 | Licensed Clinical Addiction Specialist Study Guide & Practice Questions
Methadone - (answer)prevents opioid withdrawal and craving symptoms by activating opiate receptors
in the brain. Long history of use in treatment of opioid dependence.
Buprenorphine - (answer)reduces or eliminates opioid withdrawal symptoms and reduces cravings,
without producing euphoria or dangerous side effects of heroin or other opioids. Activates and blocks
opioid receptors in the brain. Available for sublingual administration in both a stand-alone formula and
in combination with naloxone.
Naltrexone (Vivitrol or Revia) - (answer)approved for prevention of relapse in adult pts. following
complete detox from opioids. Acts by blocking brain's opioid receptors, preventing opioid drugs from
acting on them and thus blocking euphoria the user would normally feel and/or causing withdrawal if
recent opioid use has occurred. Can be taken orally or given in monthly injections
Naloxone (Narcan) - (answer)medication used to prevent opioid overdose deaths. Medication binds to
opioid receptors and can rapidly reverse or block the effects of other opioids.
Individual therapy - (answer)form of behavioral therapy that can help people learn new skills to
maintain a substance-free life, address co-occurring mental health issues, address benefits of using
prescription medication in treatment, and support individuals to pursue meaningful work, school, and
family goals
Group counseling - (answer)form of behavioral therapy that can help reduce a person's sense of
isolation, provide peer support and feedback, and develop social and problem-solving skills
Family behavior therapy - (answer)form of behavioral therapy that provides education, allows family
members to express their feelings and concerns, and helps secure the family's support for the person in
recovery
Cognitive-behavioral therapy - (answer)form of behavioral therapy; seeks to help patients recognize,
avoid, and cope with situations in which they are most likely to abuse drugs
Motivational enhancement - (answer)form of behavioral therapy; capitalizes on readiness of individuals
to change their behavior and enter treatment
